Single-dose pharmacokinetics of lamotrigine in children: Influence of age and antiepileptic comedication

Therapeutic Drug Monitoring

Volumn 23, Issue 3, 2001, Pages 217-222

  Battino, Dina ^a   Croci, Danilo ^a   Granata, Tiziana ^a   Mamoli, Daniela ^a   Messina, Sara ^b   Perucca, Emilio ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anticonvulsants; Children; Drug interaction; Lamotrigine; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ABSENCE; ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; EPILEPSY; FOCAL EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; LENNOX GASTAUT SYNDROME; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; TRIAZINES;

EID: 0035016802     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200106000-00006     Document Type: Article

References (16)

1. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference. Epilepsy Res 1999;34:1-41.
2. Perucca E. The new generation of antiepileptic drugs: Advantages and disadvantages. Br J Clin Pharmacol 1996;42:531-43.
3. Fitton A. Goa KL. Lamotrigine: An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
4. Chen C, Rudd D, Messenheimer JA, et al. Pediatric dosing recommendations of lamotrigine based on a population pharmacokinetic model. Epilepsia 1999;40 (Suppl 7):113.
5. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999;40 (Suppl 9):S7-13.
6. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997;19:252-60.
7. Battino D, Croci D, Granata T, et al. Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther Drug Monit 1997;19:620-7.
8. Armijo JA, Bravo J, Cuadrado A, et al. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 1999;21: 182-90.
9. Eriksson AS, Hoppu K, Nergardt A, et al. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996;37:769-73.
10. Vauzelle-Kervroedan F, Rey E, Cieuta C, et al. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol 1996;41:325-30.
11. Chen C, Casale EJ, Duncan B, et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy 1999;19:437-41.
12. Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia 2000;41:488.
13. Fazio A, Artesi C, Russo M, et al. A liquid chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma. Ther Drug Monit 1992; 14:509-12.
14. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: Single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
15. Yuen AWC, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-3.
16. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000;38:191-204.